Cardiff Oncology Reports Strong Phase 2 Data, Outlines Registrational Path for Onvansertib, and Extends Cash Runway
Summary
Cardiff Oncology announced positive full year 2025 financial results and a business update, reiterating robust Phase 2 clinical trial data for onvansertib in RAS-mutated mCRC and outlining plans for a registrational program, supported by a cash runway into Q1 2027.
Key Events
-
Positive Phase 2 Clinical Data Confirmed
Reaffirmed robust objective response rate (72.2%) and significant progression-free survival improvement (HR: 0.37, p<0.05) for onvansertib in first-line RAS-mutated mCRC, building on the January 27, 2026 announcement.
-
Registrational Program Planned
The company plans to advance the 30 mg onvansertib dose into a registrational program, with detailed plans expected in the first half of 2026 after discussions with the FDA.
-
Extended Cash Runway
Reported $58.3 million in cash, cash equivalents, and short-term investments as of December 31, 2025, which is sufficient to fund operations into the first quarter of 2027.
-
Full Year 2025 Financials
Reported a net loss of $45.9 million for the full year 2025, with a net loss per common share of $(0.69).
Analysis
This 8-K provides a comprehensive update, reinforcing the highly positive Phase 2 CRDF-004 trial results for onvansertib, which demonstrated a significant improvement in objective response rate and progression-free survival in first-line RAS-mutated mCRC. The company's decision to advance the 30 mg dose into a registrational program, with detailed plans expected in the first half of 2026, marks a critical step towards potential market approval. The accompanying financial results, including a cash position of $58.3 million and a runway into Q1 2027, provide the necessary liquidity to support these late-stage development efforts. While the net loss increased slightly, the overall picture is one of strong clinical momentum and financial stability for advancing its lead oncology program.
At the time of this filing, CRDF was trading at $1.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $114.5M. The 52-week trading range was $1.48 to $4.86. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.